# QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety

> **NCT04233151** · PHASE3 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 590 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** QL1203
- **DRUG:** Placebo
- **DRUG:** mFOLFOX6 regimen

## Key facts

- **NCT ID:** NCT04233151
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-20
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-07-30
- **Target enrollment:** 590 (ESTIMATED)
- **Last updated:** 2023-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233151, "QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04233151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*